Resveratrol partially corrects hematopoietic defects in Fancd2^−/− mice. (A) KSL frequency was not significantly changed in either Fancd2^−/− or Fancd2^+/+ mice after resveratrol (RV) treatment. (B) Statistical quantification of the cell-cycle analysis on KSL cells in resveratrol- versus placebo-treated mice. N = 3 for each group. (C) Representative cell cycle profiles of a placebo-treated Fancd2^−/− mouse, its resveratrol-treated Fancd2^−/− littermate control, and placebo-treated wild-type control. Cells are stained for KSL and DNA content (Hoechst 33342). Data were analyzed with FlowJo using Dean-Jett-Fox model for the quantification of each cell cycle phase. (D) Representative picture after a costaining for DNA content (Hoechst 33342) and Ki67 expression in KSL subsets of the bone marrow cells from placebo- or resveratrol-treated Fancd2^−/− mice and a placebo-treated wild-type littermate control. Percentages for each gate were denoted. (E) Resveratrol treatment significantly improved the CFU-S–forming capacity of Fancd2^−/− bone marrow cells. Data represent 3 donors for each group with 3 (or 2 in 1 case) recipients for each donor.